Intellectual Property Rights MCQs for CLAT PG, Page 2

Correct answer: A. When design protection expires, the design enters the public domain, allowing competitors to freely produce articles with the same design; increased competition tends to lower prices, which directly benefits consumers

The passage reasons as follows: 'when design protection expires, the design enters the public domain, enabling competitors to produce articles bearing the same design freely, contributing to competition and ultimately lower prices for consumers.' This causal chain - expiry of design protection leads to public domain, which enables competition, which lowers prices for consumers - is the basis for calling the limitation a 'consumer protection mechanism.' The shorter term of design protection (compared with copyright) ensures that industrial designs enter the public domain sooner, allowing competition in the market for those designed articles. This is a classic intellectual property policy argument: limited-term monopolies promote innovation during the protected period but eventually expire to benefit consumers through competition.

Source note: Designs Act 2000

Correct answer: C. The copyright in the design ceases, meaning the work can no longer be protected through copyright and must instead seek protection under the Designs Act, 2000

The passage states clearly: 'where a design is capable of being registered under the Designs Act and the author or a person authorised by the author applies it to any article more than fifty times by an industrial process, the copyright in the design ceases.' Once the fifty-article threshold is crossed, copyright protection is lost and the design can only be protected under the Designs Act, 2000. The passage explains this as a deliberate legislative policy: when an artistic work enters industrial-scale production, the appropriate protection regime shifts from copyright to design protection, which carries a shorter term. This prevents manufactures from using the exceptionally long copyright term to protect what are, in substance, industrial designs.

Source note: Designs Act 2000, Section 11; Copyright Act 1957, Section 15(2); Bharat Glass Tube Ltd. v. Gopal Glass Works Ltd., (2008) 37 PTC 1 (SC)

Correct answer: D. Prior to the Doha Declaration, there was significant legal uncertainty about whether the TRIPS Agreement permitted developing countries to exercise compulsory licensing for pharmaceutical patents in public health emergencies; the Declaration clarified that TRIPS flexibilities (including compulsory licensing under Articles 31 and 31bis) are available to all members for public health purposes, removing doubt that had been used by pharmaceutical companies and some developed countries to pressure developing nations not to exercise these rights

The Doha Declaration on the TRIPS Agreement and Public Health (WT/MIN(01)/DEC/2, November 2001) was a landmark political statement adopted at the WTO Ministerial Conference in Doha, Qatar. It was motivated by access-to-medicines crises (particularly HIV/AIDS in sub-Saharan Africa) and the pressure that pharmaceutical companies and some developed country governments had placed on developing countries not to use TRIPS compulsory licensing flexibilities. The Declaration: (1) affirmed that TRIPS should be interpreted and implemented in a manner supportive of WTO members' right to protect public health; (2) confirmed that each member has the right to grant compulsory licences and the freedom to determine the grounds; (3) confirmed each member's right to determine what constitutes a national emergency; and (4) agreed to find a solution for countries with insufficient manufacturing capacity - resolved through the 2003 'Paragraph 6 Decision' (implemented as TRIPS Article 31bis). The Declaration was not a formal TRIPS amendment but a politically significant interpretive guidance that rebalanced the IP-public health relationship.

Source note: Doha Declaration on TRIPS and Public Health, 2001

Correct answer: A. TRIPS establishes minimum standards for what inventions must be patentable (novelty, inventive step, industrial application) but leaves countries significant discretion to define the standards for these criteria in their domestic law; India exercises this flexibility through Section 3(d) of the Patents Act which sets a higher standard for pharmaceutical patent applications - requiring enhanced efficacy over known substances - to prevent 'evergreening' (minor modifications of existing drugs extended by new patents)

TRIPS Article 27 establishes that patents shall be available for any invention that is new, involves an inventive step, and is capable of industrial application (the three universal criteria). However, TRIPS leaves member states significant latitude in how they define these criteria domestically. India exercises this latitude through Section 3(d) of the Patents Act, 1970, which provides that new forms (salts, esters, polymorphs, isomers, etc.) of known substances are not patentable unless they result in significantly enhanced known efficacy. This provision is India's primary tool against pharmaceutical 'evergreening' - the practice of making minor modifications to existing drugs (such as changing a salt form) and patenting the modified form to extend effective market exclusivity. In Novartis AG v. Union of India (2013), the Supreme Court upheld Section 3(d) as TRIPS-consistent, confirming India's right to apply higher patentability standards for pharmaceutical patents. TRIPS-plus FTA provisions sometimes seek to restrict or circumscribe this discretion, which is why India resists them.

Source note: India FTA negotiations; TRIPS-plus

Correct answer: B. Gi protection is limited to products linked to a specific geographical origin and produced by an identifiable community in that region; TCEs that are not product-based (such as songs, dances, oral traditions) or that are shared across multiple geographic regions or communities do not fit within the gi framework, leaving most TCEs unprotected

The passage identifies GI protection as providing partial TCE protection but only for 'certain traditional products where the expression is tied to a specific geographical origin and a definable production community.' The limitation is inherent in the GI concept: GIs protect the commercial use of geographical names in connection with products from a specific place. A Kanchipuram silk saree is a product linked to a specific community in a specific location - GI protection works well for this. But many TCEs are not product-based: a dance tradition, a ceremonial song, an oral narrative, or a textile pattern shared across multiple tribes in a broad geographical region cannot easily be fitted into the GI framework. The GI requires a specific place-product nexus that many cultural expressions simply do not have. This explains why the passage describes GI protection as a partial and incomplete solution that does not address the full range of TCEs.

Source note: GI Act 1999; TCE protection

Correct answer: C. The gi is held collectively, typically by an association of producers or a public body such as the Tea Board, acting as the registered proprietor on behalf of all qualifying producers; individual producers use the gi as authorised users without paying royalties to each other, and no individual producer has the right to prevent others in the region from using the gi

The passage establishes the community nature of GI rights: every qualifying producer in the region is entitled to use the GI, and no single producer can monopolise it. In practice, GIs are held by representative bodies - such as the Tea Board of India for Darjeeling tea - which register the GI on behalf of the community of producers and set the product specifications that producers must meet to qualify as authorised users. Individual producers do not pay royalties to each other; the GI is the common heritage of the community. The passage does not suggest government ownership or private licensing authority. Option C is incorrect because GI protection is specifically tied to geographical origin - only producers in the designated region can use the GI.

Source note: GI Act 1999

Correct answer: B. The conflict is resolved through temporal priority: a gi that pre-dates the trade mark application generally blocks that application, while a trade mark registered in good faith before the gi was legally recognised may be permitted to co-exist

The passage states explicitly: 'the legal resolution depends on the temporal and evidentiary facts of each case' and identifies the governing principle as temporal priority: 'a GI that pre-dates a trade mark application will generally block that application, while a trade mark registered in good faith before the GI was legally recognised may be permitted to co-exist.' This principle of temporal priority - earlier in time is stronger in right - is a fundamental concept in intellectual property law that resolves conflicts without automatically privileging one form of IP over another. Options A and B both state absolute hierarchies that the passage rejects. Option D misplaces the forum of resolution to the WTO, which is an international trade disputes mechanism, not an arbiter of domestic IP conflicts.

Source note: Trade Marks Act 1999, Sections 25-26; GI Act 1999, Section 24

Correct answer: D. The non-replicability of the conditions is the factual foundation for gi protection: since the qualities of Darjeeling tea are inseparably linked to and arise from the unique geographical conditions of the Darjeeling hills, a gi is justified in preventing producers outside the region from using the name 'Darjeeling tea, ' because their tea - however high its quality - cannot genuinely possess the same geographical character

The passage's point about non-replicability is directly relevant to the justification for GI protection. A geographical indication is warranted precisely when the qualities of a product are so closely tied to a specific place that they cannot be reproduced elsewhere. If tea grown in Assam could have the same flavour, aroma, and character as Darjeeling tea, there would be no meaningful distinction and the GI would be merely a territorial label. But because the altitude, soil chemistry, rainfall, and human expertise of the Darjeeling hills create a genuinely distinctive product that cannot be manufactured elsewhere, the GI functions as an honest indicator of quality and origin. Allowing producers outside the region to use the Darjeeling name would deceive consumers about the geographical character of what they are buying. The legal protection is therefore justified by the commercial and sensory reality that the name 'Darjeeling tea' means something specific and non-replicable.

Source note: GI Act 1999

Correct answer: A. A trade mark's value derives from an individual's brand investment, whereas a gi's value derives from the collective heritage - natural conditions, generational expertise, and cultural traditions - of an entire community; accordingly, a gi confers a community right rather than an individual exclusive right

The passage draws the conceptual distinction clearly: 'A trade mark derives its value from the investment of an individual or entity in building a brand' while 'A geographical indication, by contrast, derives its value from centuries of collective knowledge, accumulated expertise, specific natural conditions, and the cultural heritage of an entire community.' The Darjeeling tea example illustrates this: the tea's flavour arises from altitude, soil, rainfall, and generational expertise - conditions and skills that 'no single producer owns and that cannot be replicated elsewhere.' The consequence of this difference in the source of value is a difference in the nature of the right: a trade mark is exclusive to one owner, while a GI is a community right available to all qualifying producers in the region. Options A, C, and D either misstate the law or introduce considerations not discussed in the passage.

Source note: Geographical Indications of Goods (Registration and Protection) Act 1999; TRIPS Agreement, Articles 22-24

Correct answer: A. India would support extension because, as the passage implies, products like Darjeeling tea are precisely the type of geographically distinctive, community-heritage goods that suffer from the same misappropriation problems as wines and spirits; enhanced protection would prevent deceptive use of the name regardless of whether the true origin is disclosed

This question requires inference from the passage combined with knowledge of TRIPS and India's negotiating position. The passage explains that the GI Act protects collective heritage products whose quality is attributable to geographical origin. Darjeeling tea is precisely such a product. Article 23's enhanced protection prevents use of a GI even with qualifying language (such as 'Darjeeling-style tea from Assam'), which is stronger than Article 22's basic protection that only covers misleading use. The passage's description of the distinctive, non-replicable character of Darjeeling tea makes clear why enhanced protection is justified: even a labelled disclaimer ('not from Darjeeling') does not fully eliminate the commercial advantage derived from using the prestigious name. India has consistently advocated in WTO negotiations for the extension of Article 23 protection to traditional agricultural and craft products for precisely this reason, which the passage's analysis supports.

Source note: TRIPS Agreement, Articles 22-24; GI Act 1999

Correct answer: C. Under the Paris Convention, a country must ensure that foreign nationals receive the same procedural treatment as domestic nationals when applying for IP protection, but the country remains free to set its own standards for what constitutes a patentable invention, the term of protection, and the rights conferred by registration

The passage makes the procedural/substantive distinction explicit: Paris 'regulated the procedural rights of foreign nationals without prescribing the content of national IP laws.' National treatment (Article 2 of Paris) means foreign nationals must receive the same treatment as domestic nationals in the host country's IP system - but this says nothing about what that system must contain. Country A may have very strong patent protection and Country B may have very weak patent protection; Paris requires both to extend their respective protections equally to each other's nationals, but it does not require them to change their substantive standards. TRIPS changed this by adding substantive minimum standards on top of the procedural equality of Paris. This distinction is why TRIPS was a 'paradigm shift' - it moved from procedural equality to substantive harmonisation with enforceable minimum content.

Source note: Paris Convention 1883

Correct answer: B. National treatment (each member state must grant foreign nationals the same IP protection as its own nationals) and the right of priority (an applicant who has filed in one member state can claim that filing date in other member states if they file within the prescribed period)

The passage explicitly identifies both principles of the Paris Convention: 'The first is national treatment (Article 2): each member state must grant to nationals of other member states the same protection it grants to its own nationals. The second is the right of priority (Article 4): an applicant who has filed an application for a patent, trade mark, or design in any member state acquires the right to file corresponding applications in other member states within a specified period.' Option A invents principles not mentioned in the passage. Option C attributes substantive harmonisation to the Paris Convention, which the passage explicitly says it did NOT achieve. Option D attributes MFN treatment to Paris, which is actually a TRIPS principle.

Source note: Paris Convention 1883; TRIPS Agreement 1994; WIPO

Correct answer: A. Compliance with IP standards became a condition for participation in the international trading system, giving developed countries that export IP-intensive goods leverage to enforce IP standards globally; India's 1999-2005 IP law amendments were substantially driven by this TRIPS pressure

The passage states: 'The integration of IP into trade law transformed the political economy of intellectual property: compliance with IP standards became a condition for participation in the international trading system, giving developed country exporters of IP-intensive goods powerful leverage to enforce IP standards globally.' The passage then illustrates this with India's experience: 'India's amendments to its patent, trade mark, and copyright laws between 1999 and 2005 were substantially driven by the need to comply with TRIPS obligations.' This represents a structural shift in how IP standards are enforced: instead of relying on goodwill or persuasion (as under Paris and Berne), TRIPS uses market access leverage - the threat of trade sanctions - to ensure compliance. Option A reverses the direction of leverage. Option C attributes enforcement power to WIPO, which the passage indicates is merely an administrator. Option D introduces a non-existent institution.

Source note: TRIPS Agreement 1994; India's IP law amendments

Correct answer: B. Patent: 1 January 2026; Trade mark: 1 July 2025

The passage states the priority periods clearly: 'twelve months for patents, six months for trade marks and designs.' Applying these periods to the facts: the patent application filed on 1 January 2025 gives the company until 1 January 2026 (twelve months later) to file the corresponding patent applications in France and the United States while claiming the 1 January 2025 priority date. The trade mark application filed on 1 January 2025 gives the company until 1 July 2025 (six months later) to file the corresponding trade mark applications in France and the United States while claiming the priority date. Option A correctly matches the patent to a twelve-month deadline and the trade mark to a six-month deadline. Options B, C, and D either reverse the periods or apply the same period to both, which is incorrect.

Source note: Paris Convention 1883, Article 4

Correct answer: D. For the first time in international trade law, TRIPS incorporated binding minimum standards of substantive IP protection into a multilateral trade agreement, with WTO dispute settlement providing enforceable sanctions for non-compliance, transforming IP standards from aspirational norms into enforceable trade obligations

The passage identifies the paradigm shift in precise terms: 'For the first time in international trade law, binding minimum standards of substantive intellectual property protection were incorporated into a multilateral trade agreement, with the WTO dispute settlement system providing enforceable sanctions for non-compliance.' Two elements constitute the shift: first, the imposition of binding minimum substantive standards (not merely procedural rules like Paris); and second, the availability of enforceable sanctions through the WTO dispute settlement mechanism. Before TRIPS, international IP conventions (Paris, Berne) had no effective enforcement mechanism; TRIPS changed this fundamentally. Options A and D overstate harmonisation. Option C is factually incorrect (TRIPS requires life plus fifty years as the minimum for most works, not seventy from publication).

Source note: TRIPS Agreement 1994

Correct answer: D. Holding an sep, even in technology essential to a major standard, does not automatically mean the patent holder holds a dominant position in the relevant market for competition law purposes; dominance must be assessed with reference to a properly defined relevant market, and the relevant market for competition purposes may be different from the technology standard itself; however, where dominance is established, abusive pricing or refusal to licence on frand terms can constitute an abuse of dominant position under Section 4 of the Competition Act, 2002

The passage carefully qualifies its statement: market position from holding SEPs is 'significant' but does not 'automatically constitute dominance.' This reflects the legal requirement that dominance under Section 4 of the Competition Act, 2002 must be established through proper market definition and assessment of market power. The relevant market must first be defined (whether by technology market, product market, or geographic market), and then the firm's position within that market must be assessed. The fact that a technology is part of a standard does not automatically establish that the SEP holder is dominant: there may be multiple competing standards (e.g., competing wireless technologies), alternative implementations, or other factors limiting market power. Once dominance is established, Section 4 of the Competition Act prohibits its abuse, including through imposing unfair or discriminatory conditions in licensing agreements. The Delhi High Court in Ericsson v. CCI (2016/2023) confirmed that competition law jurisdiction coexists with patent law jurisdiction in this space.

Source note: Ericsson v. CCI; Competition Act 2002

Correct answer: A. Not necessarily identical; 'non-discriminatory' means that similarly situated licensees are treated similarly, but licensees in different positions (different volume of products, different markets, different portfolio cross-licensing positions) may legitimately receive different terms; the requirement is consistency of approach and absence of unjustified discrimination, not mathematical equality

The passage states that FRAND's non-discrimination requirement means 'similarly situated licensees should receive equivalent terms.' The key phrase is 'similarly situated': the non-discrimination requirement does not demand that all licensees receive identical rates regardless of their circumstances. A high-volume manufacturer producing millions of devices per year and a small start-up producing thousands are not similarly situated from a commercial perspective. Additionally, cross-licensing arrangements (where one party also holds valuable patents that the SEP holder wishes to licence) may affect the effective licence rate. What the non-discrimination requirement prohibits is unjustified differential treatment between licensees who are in the same or closely comparable commercial positions - for example, offering one manufacturer a 1% royalty and another manufacturer in an identical position a 5% royalty for the same licence. The FRAND standard thus requires consistency of methodology and absence of arbitrary discrimination, not mathematical uniformity.

Source note: Ericsson v. Lava; FRAND obligations

Correct answer: B. It addresses the 'hold-up' problem: once a manufacturer has committed to a standard (by designing products around it), the sep holder gains leverage far beyond the patent's actual value because switching to a different standard is prohibitively expensive; calibrating royalties to technical contribution (rather than to the lock-in leverage) prevents sep holders from exploiting post-adoption market power to extract supra-competitive royalties

The 'hold-up' problem is one of the central policy concerns in SEP-FRAND economics. Before a standard is adopted, patent holders compete on the merits to have their technology included. After adoption, the dynamic changes fundamentally: manufacturers who have already committed to the standard (by designing and manufacturing compliant products) cannot easily switch to an alternative, giving the SEP holder enormous bargaining leverage that bears no relationship to the patent's actual value or contribution. If royalties were allowed to reflect this post-adoption market leverage, SEP holders could demand a substantial fraction of the product's entire value simply because their patent is one of many thousands in a standard. The FRAND principle of tying royalties to the actual technical contribution of the patent addresses this by requiring that the royalty reflect what the parties would have agreed in a hypothetical negotiation before the standard was adopted, when the patent holder had only competitive (not standard-lock-in) leverage.

Source note: FRAND royalty methodology

Correct answer: D. Once a technical standard is adopted, every manufacturer producing compliant devices must use the sep holder's patented technology because the standard cannot be implemented without infringing the sep; the technology cannot be designed around without abandoning the standard

The passage explicitly explains the structural advantage: 'once a technology standard is adopted... every manufacturer who produces compliant devices is obligated to use the standard and therefore to use the SEP holder's patented technology.' This is the core of the SEP problem: unlike ordinary patents (where competitors can design around the patent by using an alternative technology), SEPs are by definition technology that cannot be avoided if a product is to be standard-compliant. A mobile phone manufacturer wishing to produce devices that work on 4G networks must implement the 4G standard, which means they must implement the patented technologies that are essential to the 4G standard. This structural lock-in gives SEP holders disproportionate bargaining power - the ability to demand any royalty they choose because the alternative is not implementing the standard and therefore not being able to produce compliant products.

Source note: Ericsson v. Lava (Delhi High Court, 2024); Ericsson v. Intex (Delhi High Court, 2023)

Correct answer: C. The frand commitment is a bilateral obligation: it protects implementers who negotiate in good faith and accept reasonable terms, but does not protect those who use the frand framework merely as a delaying tactic to avoid paying any royalties while continuing to profit from implementing the standard; a court may grant an injunction against an unwilling licensee, removing the benefit of continued use pending a licence being agreed

The unwilling licensee concept is pivotal in SEP-FRAND disputes because it determines whether an injunction (ordering cessation of use of the technology) can be granted as a remedy. The FRAND commitment creates a form of licensing obligation: SEP holders who have made FRAND commitments generally cannot refuse to licence those who genuinely wish to take a FRAND licence. However, the obligation is conditional on the implementer actually being willing to negotiate and accept FRAND terms. If an implementer uses the FRAND negotiation process merely as a delaying tactic - continuing to sell infringing products for years while nominally 'negotiating' - this constitutes bad faith and makes the implementer an 'unwilling licensee.' Courts treat unwilling licensees differently: they do not benefit from the usual restraint that courts exercise in granting injunctions against FRAND-committed SEP holders. As confirmed in Ericsson v. Lava and Ericsson v. Intex (2023), Indian courts are prepared to grant injunctive relief against unwilling licensees, creating commercial pressure to conclude FRAND licences in good faith.

Source note: Ericsson v. Intex (Delhi High Court, 2023)

Correct answer: C. The risk that a patentee may not make their patented drug available at an affordable price or may not adequately work the patent in India; a compulsory licence can be granted to a generic manufacturer to address these failures, reinforcing the principle that the patent system must serve the public interest

The passage states that the compulsory licensing framework 'reinforce[s] India's commitment to ensuring that the patent system serves the public interest' and identifies two specific triggers: (a) a patentee who 'does not make their drug available at a reasonably affordable price' and (b) a patentee who 'does not adequately work the patent in India.' The Natco v. Bayer (2013) case is cited as a demonstration of this framework in action. The passage frames the compulsory licensing power as a corrective mechanism against the abuse of patent monopoly that results in unaffordable medicines or non-working of patents. This is consistent with the TRIPS Agreement's flexibilities (as affirmed by the Doha Declaration) that allow WTO members to override patent rights in the public interest. Options A, C, and D misrepresent the purpose and operation of the compulsory licensing regime.

Source note: Patents Act 1970, Sections 83, 84; Natco Pharma Ltd. v. Bayer Corporation (2013)

Correct answer: B. As the largest supplier of generic medicines to low- and middle-income countries, India has a systemic interest in ensuring that evergreening does not block generic production and pricing, because evergreening-enabled high prices would prevent affordable medicines from reaching patients globally who depend on Indian generics

The passage draws the connection explicitly: India is 'the largest supplier of generic medicines to low- and middle-income countries' and therefore had 'a particularly acute interest in preventing evergreening from pricing life-saving medicines out of reach.' The logic is systemic: if evergreening allows pharmaceutical companies to extend monopoly pricing on essential drugs, then generic manufacturers cannot produce affordable versions. Since India is the primary source of affordable generic medicines for much of the developing world, evergreening-enabled price barriers would harm patients globally who depend on Indian generics. Section 3(d) is thus not merely a domestic patent law provision but an internationally significant measure that protects the global supply chain of affordable medicines. Option C misrepresents India's motivation as protectionism rather than public health.

Source note: Patents Act 1970; India's pharmaceutical industry

Correct answer: A. Efficacy means therapeutic efficacy - the ability to produce a curative or therapeutic effect in a patient - not merely improved physical or chemical properties that do not translate into demonstrated improved therapeutic outcomes

The passage is explicit on this point: the Supreme Court held that 'efficacy' in Section 3(d) means 'specifically therapeutic efficacy - the ability of the compound to produce a curative or therapeutic effect in a patient - and not merely improved physical or chemical properties such as greater solubility, reduced hygroscopicity, or enhanced stability during storage.' The court applied this definition to reject Novartis's application: the beta-crystalline polymorph of Imatinib Mesylate had demonstrated better flowability and reduced water absorption (improved physical properties) but Novartis had not demonstrated that these properties translated into significantly enhanced therapeutic efficacy. The passage's contrast between physical/chemical properties (not sufficient) and therapeutic efficacy (required) is the core of the court's reasoning.

Source note: Novartis AG v. Union of India, (2013) 6 SCC 1

Correct answer: D. Evergreening - the strategy of extending an effective drug monopoly beyond the original patent term by obtaining new patents on minor chemical modifications of the drug, thereby blocking generic entry and maintaining high prices

The passage defines evergreening with precision: 'the strategy by which pharmaceutical companies extend their effective monopoly over a drug beyond the original patent term by making minor, incremental modifications to the drug's chemical form and obtaining new patents for each modification, thereby successively blocking generic entry and maintaining high prices.' Section 3(d) is identified as the direct statutory response to this practice. The provision requires demonstration of 'significantly enhanced efficacy' for new forms of known substances precisely to prevent the grant of successive patents on minor variants of the same chemical compound that do not provide genuine therapeutic improvement. Options A, C, and D describe practices unrelated to evergreening.

Source note: Patents Act 1970, Section 3(d); Novartis AG v. Union of India, (2013) 6 SCC 1

Correct answer: D. The amendments simultaneously fulfilled India's TRIPS obligations (by introducing product patent protection for pharmaceuticals, twenty-year patent terms, etc.) and incorporated TRIPS flexibilities (such as Section 3(d) to prevent evergreening, compulsory licensing provisions, and the Bolar research exemption) that allowed India to comply with TRIPS while protecting public health

The passage describes the 2005 amendments as achieving a dual objective: conformity with TRIPS global standards on the one hand (which required India to introduce product patent protection for pharmaceuticals, consistent with TRIPS Article 27's non-discrimination requirement) and, on the other hand, embedding 'carefully calibrated safeguards' (Section 3(d), Section 84 compulsory licensing, Section 83 working requirements) designed to utilise the TRIPS flexibilities affirmed by the Doha Declaration to protect public health. This dual character is precisely the balance that India, along with other developing countries, negotiated in the TRIPS Agreement: minimum standards of patent protection are obligatory, but the Agreement also provides significant flexibilities that members may use. The passage does not describe the amendments as cosmetic, protectionist, or as introducing automatic compulsory licensing.

Source note: Patents Act 1970, 2005 Amendment; TRIPS Agreement

Correct answer: C. Without dedicated legislation, the scope of personality rights is uncertain and varies from case to case; enforcement depends on expensive, case-by-case litigation before High Courts.

The passage implicitly highlights the limitations of developing personality rights purely through constitutional and common law principles by noting that they 'have historically been developed through a combination of constitutional guarantees and common law principles rather than dedicated legislation.' The disadvantages of this approach include: (a) uncertainty - the precise scope of protection, what constitutes infringement, and what defences are available are determined incrementally through litigation rather than clear statutory definitions; (b) inaccessibility - enforcement requires High Court litigation, which is expensive and beyond the reach of most individuals; (c) absence of criminal remedies - unlike copyright (Section 63) or trade marks (Section 103), personality right infringement has no criminal dimension under current Indian law, limiting deterrence; and (d) no registration system - unlike trade marks or patents, there is no registration mechanism for personality rights that would provide public notice of claimed rights. These limitations suggest that India may benefit from a dedicated personality rights or right of publicity statute.

Source note: Personality rights; Digital Personal Data Protection Act 2023

Correct answer: A. Generally yes; the right of publicity and personality rights are primarily concerned with the unauthorized commercial exploitation of a celebrity's identity - using their image to sell products, in advertising, or in other commercial contexts that create a false impression of endorsement; news reporting, commentary, biographical accounts, and editorial uses serve the public interest and are generally not within the scope of personality right claims

The passage's description of personality rights as protecting the 'commercial use of name, voice, image, likeness, and persona' and the 'right to protect one's commercial persona' implies a commercial focus. Personality rights are not absolute controls over all appearances or mentions of a person; they are specifically concerned with unauthorised commercial exploitation - using a person's identity to sell products, in advertising, in merchandise, or in AI-generated content that mimics their commercial persona. News reporting, journalism, criticism, parody, biography, and documentary work involve different considerations grounded in free expression under Article 19(1)(a) of the Constitution. Courts globally, including in India, recognise that the public interest in news reporting and commentary generally prevails over personality right claims in editorial contexts. This is why newspapers can publish photographs of celebrities at public events without consent: the publication serves a news or editorial purpose rather than commercially exploiting the celebrity's identity.

Source note: Personality rights doctrine